NICE U turns to offer olaparib for breast and prostate cancer following discount deal
BMJ 2023 ; 381 doi: https://doi.org/10.1136/bmj.p814 (Published 11 April 2023) Cite this as: BMJ 2023;381:p814
- Elisabeth Mahase
- The BMJ
The National Institute for Health and Care Excellence (NICE) has recommended olaparib for some types of early breast cancer and advanced prostate cancer in new draft guidelines, 1 after previously rejecting it over price. 2 3
The decision to reverse the rejection comes after a deal was negotiated between NHS England and manufacturer AstraZeneca to provide the treatment at a lower price. NICE …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42
(
excludes VAT
)
You can download a PDF version for your personal record.